SORT1 and ovarian cancer: TH1902 was demonstrated to recognize and exploit SORT1 functions, and to efficiently inhibit in vitro cell proliferation, and in vivo growth of xenografts from gynecological cancers including triple-negative breast cancer (TNBC)-derived MDA-MB-231 cells, ovarian cancer-derived ES2 and SKOV3 cells, as well as endometrial cancer-derived AN3-CA cells [24,25].